Regencell Bioscience Holdings Limited (NASDAQ:RGC) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 20%, resulting in a US$69m rise in the company's market capitalisation. In other words, the original US$6.0m purchase is now worth US$7.1m.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
See our latest analysis for Regencell Bioscience Holdings
Regencell Bioscience Holdings Insider Transactions Over The Last Year
The Founder Yat-Gai Au made the biggest insider purchase in the last 12 months. That single transaction was for US$3.9m worth of shares at a price of US$29.29 each. That means that an insider was happy to buy shares at around the current price of US$32.28. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider bought shares at close to current prices. The only individual insider to buy over the last year was Yat-Gai Au.
Yat-Gai Au purchased 219.49k shares over the year. The average price per share was US$27.41. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
![insider-trading-volume](https://usnewsfile.moomoo.com/pic/0-14466865-0-fd1afc29ad5ecb8417d28d0b90e0cbbe.png/big)
NasdaqCM:RGC Insider Trading Volume September 7th 2022
Regencell Bioscience Holdings is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insider Ownership
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$341m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Does This Data Suggest About Regencell Bioscience Holdings Insiders?
The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest Regencell Bioscience Holdings insiders are well aligned, and quite possibly think the share price is too low. Nice! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that Regencell Bioscience Holdings has 2 warning signs (1 is a bit unpleasant!) that deserve your attention before going any further with your analysis.
But note: Regencell Bioscience Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
脑再生科技控股有限公司纳斯达克(Sequoia Capital:RGC)过去一年买入股票的内部人士上周获得了丰厚回报。该股上涨20%,导致该公司市值增加6900万美元。换句话说,最初的600万美元收购现在价值710万美元。
尽管我们不认为股东应该简单地跟踪内幕交易,但我们确实认为,密切关注内部人士的所作所为是完全合乎逻辑的。
查看我们对脑再生科技控股的最新分析
脑再生科技控股过去一年的内幕交易
创始人区逸盖在过去12个月里进行了最大规模的内幕收购。这一笔交易是以每股29.29美元的价格收购价值390万美元的股票。这意味着一位内部人士乐于以目前32.28美元的价格买入股票。尽管他们的观点可能在收购后发生了变化,但这至少表明他们对公司的未来充满信心。如果有人以远低于当前价格的价格买入股票,总的来说这是一个好兆头,但要记住,他们可能不再看到价值。在这种情况下,我们很高兴地报告,内部人士以接近当前价格的价格购买了股票。去年唯一买入的个人内部人士是Au Yat-Gai。
Au Yat-Gai在去年购买了21.949万股股票。每股均价为27.41美元。下面的图表显示了过去一年的内幕交易(按公司和个人)。通过点击下面的图表,你可以看到每一笔内幕交易的准确细节!
![insider-trading-volume](https://usnewsfile.moomoo.com/pic/0-14466865-0-fd1afc29ad5ecb8417d28d0b90e0cbbe.png/big)
NasdaqCM:RGC内幕交易量2022年9月7日
内部人士买入的股票并不只有脑再生科技控股。所以让我们来看看这个免费内幕收购的成长型公司名单。
内部人持股
看看一家公司的内部人持股总数,可以帮助你了解他们是否与普通股股东很好地结合在一起。通常,内部人持股越高,内部人就越有可能受到激励,建立长期的公司。脑再生科技控股的内部人士持有该公司81%的股份,根据最近的股价计算,目前价值约为3.41亿美元。我喜欢看到这种程度的内部人持股,因为它增加了管理层考虑股东最佳利益的机会。
那么,这些数据对脑再生科技控股的内部人士有何启示?
最近的内部收购令人振奋。而较长期的内幕交易也给了我们信心。然而,我们注意到该公司在过去12个月里没有盈利,这让我们保持谨慎。再加上值得注意的内部人持股,这些因素表明脑再生科技控股的内部人士很好地结合在一起,很可能认为该公司的股价太低了。好的!因此,这些内幕交易可以帮助我们建立一个关于股票的论文,但了解这家公司面临的风险也是值得的。在Simply Wall St.,我们发现脑再生科技控股2个警告标志(1有点令人不快!)在进一步分析之前,这一点值得你注意。
但请注意:脑再生科技控股可能不是最值得买入的股票。所以让我们来看看这个免费高净资产收益率和低负债的有趣公司名单。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。